Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia - Wikidata - thesis-toulmin - TriplyDB

Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia

Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia

http://www.wikidata.org/entity/Q24299780

about

Role of Junctin protein interactions in cellular dynamics of calsequestrin polymer upon calcium perturbation Calsequestrin 2 and arrhythmias Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling Genetics of inherited primary arrhythmia disorders Pernicious attrition and inter-RyR2 CICR current control in cardiac muscle Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis The catecholaminergic polymorphic ventricular tachycardia mutation R33Q disrupts the N-terminal structural motif that regulates reversible calsequestrin polymerization The calsequestrin mutation CASQ2D307H does not affect protein stability and targeting to the junctional sarcoplasmic reticulum but compromises its dynamic regulation of calcium buffering Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.Catecholaminergic polymorphic ventricular tachycardia in a patient with recurrent exertional syncope Cardiac syncope.Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes.Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice Subcellular Ca2+ signaling in the heart: the role of ryanodine receptor sensitivity.Calcium handling in zebrafish ventricular myocytes.Genetics of sudden cardiac death.Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia The cardiac ryanodine receptor luminal Ca2+ sensor governs Ca2+ waves, ventricular tachyarrhythmias and cardiac hypertrophy in calsequestrin-null mice.Calcium and arrhythmogenesis.Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibition ameliorates arrhythmias elicited by junctin ablation under stress conditions Chain-reaction Ca(2+) signaling in the heart.Enhanced ryanodine receptor-mediated calcium leak determines reduced sarcoplasmic reticulum calcium content in chronic canine heart failure.Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.Luminal Ca2+ regulation of single cardiac ryanodine receptors: insights provided by calsequestrin and its mutants Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death.Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca2+ release in a genetic model of arrhythmia.Regulatory roles of junctin in sarcoplasmic reticulum calcium cycling and myocardial function.Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling.Mechanism of calsequestrin regulation of single cardiac ryanodine receptor in normal and pathological conditions.Altered Ca2+ sparks in aging skeletal and cardiac muscle.Timing in cellular Ca2+ signaling A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice.Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.

P2860

0b32052f5c41945f867b4737fd97b2486d8e366a 29d891d2b1013b08f966224c3679066181d0f289 2af9d5ab286b6168d77fc84d0ffe91fb9b5964ae 3ab54a0c3b2567e85af351e0aad815fd8746515e 69382cf14353f9e116184f13debe1ce37cb48720 74a852f0cd465f92e5bc2c8ca74e15fbc54db319 f2a89e85ea87a1ae6869869ad12dbe58f406a12a

P248

Q24298576-4FDE91DB-C45C-4C39-912B-71E61E039C43 Q24300626-C6B2612F-019E-41BB-9B6D-4901EF11723E Q24608179-3F0B71BC-D4FD-4164-B11B-7C3B8D12A6AD Q26750618-09C986F7-28D8-40B5-876A-72B0313BA88E Q26783570-723C6D67-6D66-4F07-818B-72024B041CA9 Q26861712-7DA719C3-4B69-4129-BB88-BA58A604317D Q27021919-1418A74B-051E-4F47-A8A2-99ADEF7EC3F4 Q28235110-420E9FBA-860B-4050-899B-44479A081CAE Q28262015-20E7950D-0AD6-4E53-88DB-A416F06F1FB7 Q28308142-9C97F3BC-BBB2-462C-8D38-D6DD85CDCF24 Q28576166-528CD370-A61E-4244-8177-85AE605CF937 Q28589131-26676699-2A9E-4A0F-93C1-43A94F4B2008 Q30498471-60350437-9241-4F4B-B015-E3A8AE33E9A6 Q33160416-366648F6-60AC-474C-B891-0097DF2C3997 Q33161060-4E0C5369-BD99-4452-A3DB-80F17EB62014 Q33162027-A92A109A-8166-4DFF-B372-A4AB003412D1 Q33162208-E72D4E72-4D7C-4B08-B719-DB7B0932A5E6 Q33163102-19613EB1-36C8-4306-90C2-AF621324D3FA Q33919047-9F03981A-90EF-418E-ACA9-B0AA035E714D Q34028253-E28F8426-17A7-4B11-A89A-05FA33474F73 Q34142132-0094CDC4-46B2-4D86-8B43-45696E4899CD Q34203505-4DDC845A-F61A-441F-81C2-CB5DC9084C49 Q34629553-FE100F34-DBA9-44EB-B75B-7C39D36E517B Q34775590-15BF1DAF-F12C-414E-97E5-ACBD1C5693F9 Q35095089-3AD7D188-7BC8-4D46-8551-F21000E0FB23 Q35798054-C5E84C17-B8AF-4E77-A998-4373DDCED055 Q35865391-7DCFA220-57E8-4F6F-B034-A70DB4EFEE1C Q36156470-98AA2941-0EC1-4DC8-B7B0-17E82B38FCA3 Q36169155-8143ABE0-7575-4F56-B91A-C0CD7B5AD371 Q36517742-127955B0-8CEA-4990-A26C-37EDF33B6AB6 Q36791253-B7BD8AD9-BD16-4045-BE6A-7A21414680A4 Q36853107-D5D3F7D8-4BA3-4E17-A105-AE92949C3737 Q36950453-B20FE975-0D78-4016-9AC6-C560FE52CA10 Q36995841-F355CDE7-26E7-4A14-A182-EEC5042EE1D8 Q37025197-6944AFC8-7838-48F2-85AA-F0E8C5B7E855 Q37055484-A51E530E-E084-4936-B6D9-AE28A0F9BA97 Q37083890-0FB36905-14E4-471A-BB11-4BDB629B4A16 Q37266758-1D01D18B-27F7-48B5-A4E7-ECC4CC090A2D Q37278605-6D9B3BA7-AA1B-494B-B2AC-3C81C4D5CD30 Q37294805-83B53EC7-A3FC-4113-9B3D-ED82D2FE72AF

P2860

Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia

http://www.wikidata.org/entity/Q24299780

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Clinical phenotype and functio ...... orphic ventricular tachycardia

@ast

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en-gb

Clinical phenotype and functio ...... orphic ventricular tachycardia

@nl

type

label

Clinical phenotype and functio ...... orphic ventricular tachycardia

@ast

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en-gb

Clinical phenotype and functio ...... orphic ventricular tachycardia

@nl

prefLabel

Clinical phenotype and functio ...... orphic ventricular tachycardia

@ast

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en-gb

Clinical phenotype and functio ...... orphic ventricular tachycardia

@nl

P1433

Q24299780-4FFC8DA0-C43B-4026-A8EA-0C3222149915

P1476

Q24299780-6B2D61CC-FB8B-4468-8551-4A532B997548

P2093

Q24299780-2B852207-C4D5-4340-B5C6-9BD4A1E585B0

Q24299780-351D2A35-0248-43A6-B13A-C3D77BFA2365

Q24299780-394965E1-A581-46FB-9F67-4BC5BC0087F2

Q24299780-396C6C1C-C2A9-427F-9F0A-15E6C5D22741

Q24299780-662B4985-F34A-4B29-8CF8-299EAF664111

Q24299780-7369A05E-26CA-41DA-923E-8F12DF64C729

Q24299780-89CDB5E2-E029-46DF-A8B7-6068E8A91E5F

Q24299780-92BD44C2-DDF6-41B6-994A-F23F4F7FFE02

Q24299780-C479F3F2-5F88-4678-B758-E4574EF76702

Q24299780-DF33E39E-98B5-4092-9E1B-0AAB5BD6F9BC

P304

Q24299780-DA562D15-C2A5-4E9E-9335-2456CA541AEE

P31

Q24299780-7EDB30E4-C41E-4770-A298-EABCA2314D44

P3181

Q24299780-8F8C0174-9E3D-44EF-998F-6376A1D9924B

P356

Q24299780-944D0803-9B29-423F-BA65-93357903ABDC

P407

Q24299780-D1F06F80-2E25-4995-8734-1771C1DF421D

P433

Q24299780-4F22E82D-DC9F-43A9-A793-7FCB1286F9D6

P478

Q24299780-E15BC67B-27AA-43D9-BB60-86E90153E0CA

P577

Q24299780-66EA520E-E225-4C91-B0AC-9F50C0403940

P698

Q24299780-01DA4B22-9523-480B-B9C2-5821B1E50C02

P921

Q24299780-4C1E4B2E-7CCC-4F77-82E5-BD58F89B8693

Q24299780-D10B849C-6ECB-4245-B393-C3D13EC3740F

Q24299780-DC57C554-7198-4EFF-B256-433E8C0948AD

Q24299780-E54F48AF-DE41-470D-A365-AC8A58751B65

P3181

P356

CIRCULATIONAHA.106.623793

P1433

P1476

Clinical phenotype and functio ...... orphic ventricular tachycardia

@en

P2093

Alessandra Nori

http://www.w3.org/2001/XMLSchema#string

Carlo Napolitano

http://www.w3.org/2001/XMLSchema#string

Dmitry Terentyev

http://www.w3.org/2001/XMLSchema#string

Federica Turcato

http://www.w3.org/2001/XMLSchema#string

Giorgia Valle

http://www.w3.org/2001/XMLSchema#string

Marina Raffaele di Barletta

http://www.w3.org/2001/XMLSchema#string

Mirella Memmi

http://www.w3.org/2001/XMLSchema#string

Nicoletta Rizzi

http://www.w3.org/2001/XMLSchema#string

Pompeo Volpe

http://www.w3.org/2001/XMLSchema#string

Sandor Gyorke

http://www.w3.org/2001/XMLSchema#string

P304

1012-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2888367

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/CIRCULATIONAHA.106.623793

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16908766

http://www.w3.org/2001/XMLSchema#string

P921

catecholaminergic polymorphic ventricular tachycardia

cellular response to caffeine

Calsequestrin 2